Literature DB >> 11046107

Down-regulation of benzodiazepine binding to alpha 5 subunit-containing gamma-aminobutyric Acid(A) receptors in tolerant rat brain indicates particular involvement of the hippocampal CA1 region.

M Li1, A Szabo, H C Rosenberg.   

Abstract

Chronic benzodiazepine treatment can produce tolerance and changes in gamma-aminobutyric acid (GABA)(A) receptors. To study the effect of treatment on a selected population of receptors, assays were performed using [(3)H]RY-80, which is selective for GABA(A) receptors with an alpha 5 subunit. Rats were given a flurazepam treatment known to produce tolerance and down-regulation of benzodiazepine binding, or a diazepam treatment shown to produce tolerance but not receptor down-regulation. Quantitative receptor autoradiography using sagittal brain sections bound with [(3)H]RY-80 showed binding in areas known to express alpha 5 mRNA. Brains from flurazepam-treated rats showed significantly decreased 1 nM [(3)H]RY-80 binding in hippocampal formation (e.g., 32% decrease in CA1) and superior colliculus, but not other areas. Using 5 nM [(3)H]RY-80 showed similar decreases in hippocampus. A corresponding 29% decrease in B(max) but no change in K(d) was found with a filtration binding assay using hippocampal homogenates. Down-regulation of [(3)H]RY-80 binding had returned to control by 2 days after withdrawing flurazepam treatment. The magnitude of down-regulation of [(3)H]RY-80 binding suggested that GABA(A) receptors with an alpha 5 subunit may play a prominent role in the adaptive responses associated with benzodiazepine tolerance. Chronic diazepam treatment also resulted in decreased [(3)H]RY-80 binding. However, the regional selectivity was even more pronounced than in flurazepam-treated rats, and only the hippocampal CA1 region showed decreased binding (27%). This localized down-regulation persisted for several days after the end of diazepam treatment. These data indicate that synapses in the hippocampal CA1 region are particularly involved in the adaptive response to chronic benzodiazepine treatments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046107

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models.

Authors:  Felix M Rivas; James P Stables; Lauren Murphree; Rahul V Edwankar; Chitra R Edwankar; Shengming Huang; Hiteshkumar D Jain; Hao Zhou; Samarpan Majumder; Subramanian Sankar; Bryan L Roth; Joachim Ramerstorfer; Roman Furtmüller; Werner Sieghart; James M Cook
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

2.  Requirement of alpha5-GABAA receptors for the development of tolerance to the sedative action of diazepam in mice.

Authors:  Carolien van Rijnsoever; Marcus Täuber; Mohamed Khaled Choulli; Ruth Keist; Uwe Rudolph; Hanns Mohler; Jean Marc Fritschy; Florence Crestani
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

3.  Adaptive changes in the rat hippocampal glutamatergic neurotransmission are observed during long-term treatment with lorazepam.

Authors:  C Bonavita; A Ferrero; M Cereseto; M Velardez; M Rubio; S Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2003-01-24       Impact factor: 4.530

4.  Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.

Authors:  Barry E Gidal; Robert T Wechsler; Raman Sankar; Georgia D Montouris; H Steve White; James C Cloyd; Mary Clare Kane; Guangbin Peng; David M Tworek; Vivienne Shen; Jouko Isojarvi
Journal:  Neurology       Date:  2016-09-28       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.